BridgeBio Pharma (BBIO) Cash from Investing Activities (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Cash from Investing Activities data on file, last reported at -$42.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 2579.31% year-over-year to -$42.7 million; the trailing twelve-month figure through Mar 2026 stood at -$65.6 million (down 280.13% YoY), and the FY2025 full-year result was -$24.5 million, down 140.29% from the prior year.
• Cash from Investing Activities slipped to -$42.7 million in Q1 2026, from -$14.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $149.7 million in Q2 2022 to a low of -$42.7 million in Q1 2026.
• A 5-year average of $29.5 million and a median of $4.5 million in 2025 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities soared 32586.03% in 2022 and plunged 4804.55% in 2024, its largest moves.
• Tracing BBIO's Cash from Investing Activities over 5 years: stood at $18.0 million in 2022, then plunged by 100.37% to -$66000.0 in 2023, then sank by 4804.55% to -$3.2 million in 2024, then sank by 343.44% to -$14.4 million in 2025, then plunged by 197.72% to -$42.7 million in 2026.
• Business Quant data shows BBIO's Cash from Investing Activities at -$42.7 million in Q1 2026, -$14.4 million in Q4 2025, and $4.5 million in Q3 2025.